Predicting the drug safety for traditional Chinese medicine through a comparative analysis of withdrawn drugs using pharmacological network

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Xue, Mengzhu ^a   Zhang, Shoude ^a   Cai, Chaoqian ^a   Yu, Xiaojuan ^a   Shan, Lei ^b   Liu, Xiaofeng ^a   Zhang, Weidong ^b   Li, Honglin ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HESPERETIN; MITHRAMYCIN; NABILONE; PROPAFENONE; SILIBININ;

ARTICLE; CALCULATION; CENTRALIZATION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHINESE MEDICINE; COMPARATIVE STUDY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART VENTRICLE FIBRILLATION; HEPATITIS C; HUMAN; PREDICTION; PRIORITY JOURNAL; REFERENCE DATABASE;

EID: 84877956131     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/256782     Document Type: Article

References (71)

1. Stevens J. L., Baker T. K., The future of drug safety testing: expanding the view and narrowing the focus. Drug Discovery Today 2009 14 3-4 162 167 2-s2.0-58849132807 10.1016/j.drudis.2008.11.009
2. Abernethy D. R., Woodcock J., Lesko L. J., Pharmacological mechanism-based drug safety assessment and prediction. Clinical Pharmacology and Therapeutics 2011 89 6 793 797 2-s2.0-79956321442 10.1038/clpt.2011.55
3. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., Heller A., Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology 2000 32 1 56 67 2-s2.0-0033771951 10.1006/rtph.2000.1399
4. Lu Z., Technical challenges in designing post-marketing eCRFs to address clinical safety and pharmacovigilance needs. Contemporary Clinical Trials 2010 31 1 108 118 2-s2.0-73249133512 10.1016/j.cct.2009.11.004
5. Abraham J., Davis C., A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy. Social Science and Medicine 2005 61 5 881 892 2-s2.0-20444389780 10.1016/j.socscimed.2005.01.004 (Pubitemid 40805536)
6. Hauben M., Bate A., Decision support methods for the detection of adverse events in post-marketing data. Drug Discovery Today 2009 14 7-8 343 357 2-s2.0-62849083003 10.1016/j.drudis.2008.12.012
7. Moggs J., Moulin P., Pognan F., Investigative safety science as a competitive advantage for Pharma. Expert Opinion on Drug Metabolism & Toxicology 2012 8 1071 1082
8. Ishiguro C., Hall M., Neyarapally G. A., Post-market drug safety evidence sources: an analysis of FDA drug safety communications. Pharmacoepidemiology and Drug Safety 2012 21 1134 1136
9. Valerio L. G. Jr., In silico toxicology for the pharmaceutical sciences. Toxicology and Applied Pharmacology 2009 241 3 356 370 2-s2.0-70449528780 10.1016/j.taap.2009.08.022
10. Muster W., Breidenbach A., Fischer H., Kirchner S., Müller L., Pähler A., Computational toxicology in drug development. Drug Discovery Today 2008 13 7-8 303 310 2-s2.0-41549105449 10.1016/j.drudis.2007.12.007
11. Bureeva S., Nikolsky Y., Quantitative knowledge-based analysis in compound safety assessment. Expert Opinion on Drug Metabolism & Toxicology 2011 7 3 287 298 2-s2.0-79951875902 10.1517/17425255.2011.553191
12. Singh S., Loke Y. K., Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials 2012 13, article 138
13. Chandra N., Padiadpu J., Network approaches to drug discovery. Expert Opinion on Drug Metabolism & Toxicology 2013 8 7 20
14. Barabási A. L., Oltvai Z. N., Network biology: understanding the cell's functional organization. Nature Reviews Genetics 2004 5 2 101 113 2-s2.0-0742305866 10.1038/nrg1272 (Pubitemid 38160277)
15. Hopkins A. L., Network pharmacology: the next paradigm in drug discovery. Nature Chemical Biology 2008 4 11 682 690 2-s2.0-54249155522 10.1038/nchembio.118
16. Huang L. C., Wu X., Chen J. Y., Predicting adverse side effects of drugs. BMC Genomics 2011 12, supplement 5, article S11
17. Ross C. J., Visscher H., Sistonen J., Brunham L. R., Pussegoda K., Loo T. T., Rieder M. J., Koren G., Carleton B. C., Hayden M. R., CPNDS Consortium, The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology. Thyroid 2010 20 7 681 687 2-s2.0-78349268004
18. Bai J. P., Abernethy D. R., Systems pharmacology to predict drug toxicity: integration across levels of biological organization. Annual Review of Pharmacology and Toxicology 2013 53 451 473
19. Campillos M., Kuhn M., Gavin A. C., Jensen L. J., Bork P., Drug target identification using side-effect similarity. Science 2008 321 5886 263 266 2-s2.0-47249146126 10.1126/science.1158140 (Pubitemid 351989100)
20. Cami A., Arnold A., Manzi S., Predicting adverse drug events using pharmacological network models. Science Translational Medicine 2011 3 114 127
21. Yamanishi Y., Kotera M., Kanehisa M., Goto S., Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 2010 26 12 i246 i254 2-s2.0-77954230951 10.1093/bioinformatics/btq176
22. Yamanishi Y., Araki M., Gutteridge A., Honda W., Kanehisa M., Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 2008 24 13 i232 i240 2-s2.0-46249090791 10.1093/bioinformatics/btn162 (Pubitemid 351911678)
23. Itokawa H., Morris-Natschke S. L., Akiyama T., Lee K. H., Plant-derived natural product research aimed at new drug discovery. Journal of Natural Medicines 2008 62 3 263 280 2-s2.0-44949201430 10.1007/s11418-008-0246-z
24. Butler M. S., The role of natural product chemistry in drug discovery. Journal of Natural Products 2004 67 12 2141 2153 2-s2.0-11344292132 10.1021/np040106y (Pubitemid 40092578)
25. Butler M. S., Natural products to drugs: natural product derived compounds in clinical trials. Natural Product Reports 2005 22 2 162 195 2-s2.0-17844399025 10.1039/b402985m (Pubitemid 40589045)
26. Butler M. S., Natural products to drugs: natural product-derived compounds in clinical trials. Natural Product Reports 2008 25 3 475 516 2-s2.0-44249098800 10.1039/b514294f (Pubitemid 351725315)
27. Lachance H., Wetzel S., Kumar K., Charting, navigating, and populating natural product chemical space for drug discovery. Journal of Medicinal Chemistry 2012 55 5989 6001
28. Tietze L. F., Bell H. P., Chandrasekhar S., Natural product hybrids as new leads for drug discovery. Angewandte Chemie 2003 42 34 3996 4028 2-s2.0-0141427680 10.1002/anie.200200553 (Pubitemid 37128010)
29. Debelle F. D., Vanherweghem J. L., Nortier J. L., Aristolochic acid nephropathy: a worldwide problem. Kidney International 2008 74 2 158 169 2-s2.0-41549102309 10.1038/ki.2008.129 (Pubitemid 351915079)
30. Hwang Y. H., Kim T., Cho W. K., In vitro and in vivo genotoxicity assessment of aristolochia manshuriensis kom. Evidence-Based Complementary and Alternative Medicine 2012 2012 9 412736 10.1155/2012/412736
31. Wishart D. S., Knox C., Guo A. C., Cheng D., Shrivastava S., Tzur D., Gautam B., Hassanali M., DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Research 2008 36 1 D901 D906 2-s2.0-38549151817 10.1093/nar/gkm958 (Pubitemid 351149842)
32. Zhang S., Lu W., Liu X., Diao Y., Bai F., Wang L., Shan L., Huang J., Li H., Zhang W., Fast and effective identification of the bioactive compounds and their targets from medicinal plants via computational chemical biology approach. MedChemComm 2011 2 6 471 477 2-s2.0-79959270961 10.1039/c0md00245c
33. Smoot M. E., Ono K., Ruscheinski J., Wang P. L., Ideker T., Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011 27 3 431 432 2-s2.0-79551587720 10.1093/bioinformatics/btq675
34. Shannon P., Markiel A., Ozier O., Baliga N. S., Wang J. T., Ramage D., Amin N., Schwikowski B., Ideker T., Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Research 2003 13 11 2498 2504 2-s2.0-0242490780 10.1101/gr.1239303 (Pubitemid 37428274)
35. Junker B. H., Koschützki D., Schreiber F., Exploration of biological network centralities with CentiBiN. BMC Bioinformatics 2006 7, article 219 2-s2.0-33746674977 10.1186/1471-2105-7-219 (Pubitemid 44164727)
36. Ma C., Wang L., Xie X. Q., GPU accelerated chemical similarity calculation for compound library comparison. Journal of Chemical Information and Modeling 2011 51 7 1521 1527 2-s2.0-79960741112 10.1021/ci1004948
37. Willett P., Chemical similarity searching. Journal of Chemical Information and Computer Sciences 1998 38 983 996 (Pubitemid 128591261)
38. Aittokallio T., Schwikowski B., Graph-based methods for analysing networks in cell biology. Briefings in Bioinformatics 2006 7 3 243 255 2-s2.0-33748798478 10.1093/bib/bbl022 (Pubitemid 44404874)
39. Estrada E., Quantifying network heterogeneity. Physical Review E 2010 82 066102
40. Klein D. J., Centrality measure in graphs. Journal of Mathematical Chemistry 2010 47 4 1209 1223 2-s2.0-77952290197 10.1007/s10910-009-9635-0
41. Hage P., Harary F., Eccentricity and centrality in networks. Social Networks 1995 17 1 57 63 2-s2.0-0007265820
42. Kuhn M., Campillos M., Letunic I., Jensen L. J., Bork P., A side effect resource to capture phenotypic effects of drugs. Molecular Systems Biology 2010 6, article 343 2-s2.0-76149120425 10.1038/msb.2009.98
43. Cunningham D., Bradley C. J., Forrest G. J., Hutcheon A. W., Adams L., Sneddon M., Harding M., Kerr D. J., Soukop M., Kaye S. B., A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. European Journal of Cancer and Clinical Oncology 1988 24 4 685 689 2-s2.0-0023884902 (Pubitemid 18095574)
44. Niiranen A., Mattson K., Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. American Journal of Clinical Oncology 1987 10 4 325 329 2-s2.0-0023392248
45. Einhorn L. H., Nagy C., Furnas B., Williams S. D., Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. Journal of Clinical Pharmacology 1981 21 8-9 64S 69S 2-s2.0-0019605643
46. Yang Y., Wolfram J., Shen H., Hesperetin: an inhibitor of the transforming growth factor-beta (TGF-beta) signaling pathway. European Journal of Medicinal Chemistry 2012 58 390 395
47. Zarebczan B., Pinchot S. N., Kunnimalaiyaan M., Chen H., Hesperetin, a potential therapy for carcinoid cancer. American Journal of Surgery 2011 201 3 329 333 2-s2.0-79952174816 10.1016/j.amjsurg.2010.08.018
48. Ye L., Chan F. L., Chen S., The citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice. Journal of Nutritional Biochemistry 2012 23 1230 1237
49. Gaita F., Richiardi E., Bocchiardo M., Short- and long-term effects of propafenone in ventricular arrhythmias. International Journal of Cardiology 1986 13 2 163 170 2-s2.0-0022441183 (Pubitemid 16000581)
50. Vassiliadis I., Papoutsakis P., Kallikazaros I., Stefanadis C., Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. International Journal of Cardiology 1990 27 1 63 70 2-s2.0-0025253588 10.1016/0167-5273(90)90192-8 (Pubitemid 20097470)
51. Sampi K., Hozumi M., Kumai R., Honma Y., Sakurai M., Differentiation of blasts from patients in myeloid crisis of chronic myelogenous leukemia by in-vivo and in-vitro plicamycin treatment. Leukemia Research 1987 11 12 1089 1092 2-s2.0-0023576811 (Pubitemid 18049489)
52. Dutcher J. P., Coletti D., Paietta E., Wiernik P. H., A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. Leukemia Research 1997 21 5 375 380 2-s2.0-0030851551 10.1016/S0145-2126(96)00108-7 (Pubitemid 27308229)
53. Wimalawansa S. J., Dramatic response to plicamycin in a patient with severe Paget's disease refractory to calcitonin and pamidronate. Seminars in Arthritis and Rheumatism 1994 23 4 267 2-s2.0-23444453895 10.1016/0049-0172(94) 90056-6 (Pubitemid 24077107)
54. Verschoyle R. D., Greaves P., Patel K., Marsden D. A., Brown K., Steward W. P., Gescher A. J., Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels. European Journal of Cancer 2008 44 6 898 906 2-s2.0-41949087545 10.1016/j.ejca.2008.02.020
55. Yin F., Liu J., Ji X., Wang Y., Zidichouski J., Zhang J., Silibinin: a novel inhibitor of A β aggregation. Neurochemistry International 2011 58 3 399 403 2-s2.0-79951581293 10.1016/j.neuint.2010.12.017
56. Wang J. Y., Chang C. C., Chiang C. C., Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. Journal of Cellular Biochemistry 2012 113 1733 1743
57. Dastpeyman M., Motamed N., Azadmanesh K., Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of beta1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI. Medical Oncology 2012 29 2512 2518
58. Ai W., Zhang Y., Tang Q. Z., Yan L., Bian Z. Y., Liu C., Huang H., Bai X., Yin L., Li H., Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling. Journal of Cellular Biochemistry 2010 110 5 1111 1122 2-s2.0-77954909691 10.1002/jcb.22623
59. Tyagi A., Singh R. P., Ramasamy K., Raina K., Redente E. F., Dwyer-Nield L. D., Radcliffe R. A., Malkinson A. M., Agarwal R., Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor- B and signal transducers and activators of transcription 3. Cancer Prevention Research 2009 2 1 74 83 2-s2.0-62349117597 10.1158/1940-6207.CAPR-08-0095
60. Cheng B., Gong H., Li X., Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide. Biochemical and Biophysical Research Communications 2012 419 495 499
61. Barcena R., Moreno A., Rodriguez-Gandia M. A., Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. Journal of Hepatology 2013 58 421 426
62. Li L., Zeng J., Gao Y., He D., Targeting silibinin in the antiproliferative pathway. Expert Opinion on Investigational Drugs 2010 19 2 243 255 2-s2.0-74549146799 10.1517/13543780903533631
63. Liu X., Jiang H., Li H., SHAFTS: a hybrid approach for 3D molecular similarity calculation-1. Method and assessment of virtual screening. Journal of Chemical Information and Modeling 2011 51 2372 2385
64. Copeland R. A., The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety. Expert Opinion on Drug Discovery 2010 5 4 305 310 2-s2.0-77950197835 10.1517/17460441003677725
65. Bisgin H., Liu Z., Fang H., Ming FDA drug labels using an unsupervised learning technique-topic modeling. BMC Bioinformatics 2011 12, article S11
66. Shetty K. D., Dalal S. R., Using information mining of the medical literature to improve drug safety. Journal of the American Medical Informatics Association 2011 18 668 674
67. Lounkine E., Keiser M. J., Whitebread S., Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012 486 361 367
68. Keiser M. J., Setola V., Irwin J. J., Laggner C., Abbas A. I., Hufeisen S. J., Jensen N. H., Kuijer M. B., Matos R. C., Tran T. B., Whaley R., Glennon R. A., Hert J., Thomas K. L. H., Edwards D. D., Shoichet B. K., Roth B. L., Predicting new molecular targets for known drugs. Nature 2009 462 7270 175 181 2-s2.0-70449634957 10.1038/nature08506
69. Keiser M. J., Roth B. L., Armbruster B. N., Ernsberger P., Irwin J. J., Shoichet B. K., Relating protein pharmacology by ligand chemistry. Nature Biotechnology 2007 25 2 197 206 2-s2.0-33846876695 10.1038/nbt1284 (Pubitemid 46227119)
70. Hert J., Keiser M. J., Irwin J. J., Oprea T. I., Shoichet B. K., Quantifying the relationships among drug classes. Journal of Chemical Information and Modeling 2008 48 4 755 765 2-s2.0-44449159422 10.1021/ci8000259 (Pubitemid 351757743)
71. Azzaoui K., Hamon J., Faller B., Whitebread S., Jacoby E., Bender A., Jenkins J. L., Urban L., Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2007 2 6 874 880 2-s2.0-35248817286 10.1002/cmdc.200700036